Moreover, several α-synuclein oligomer-binding compounds have recently emerged as disease-modifying therapeutic candidates to reduce synucleinopathy [[45], [46], [47], [48], [49], [50]], potentially applicable for improvement of α-synuclein propagation into the grafted hiPSC-derived mDA neurons to maintain the clinical outcomes as a disease-modified therapy in long-term follow-up. Here, SNCA is linked to synucleinopathy.